The negative ANSA-RAD trial, when contrasted with the positive STAMPEDE trial, demonstrates that patient selection is paramount in adjuvant therapy. The difference in outcomes was driven by risk definition, not the drug. This reinforces that "negative" trials are clinically vital for defining which patient populations do not benefit, preventing widespread overtreatment.

The CREST trial showed benefit driven by patients with carcinoma in situ (CIS), while the Potomac trial showed a lack of benefit in the same subgroup. This stark inconsistency demonstrates that subgroup analyses, even for stratified factors, can be unreliable and are a weak basis for regulatory decisions or label restrictions.

After years of successfully intensifying hormonal therapy, the focus in prostate cancer is shifting toward de-intensification. Researchers are exploring intermittent therapy for top responders and developing non-hormonal approaches like radioligands to spare patients the chronic, life-altering side effects of permanent castration.

Even when trials like LITESPARK 022 and Keynote 564 use identical eligibility criteria, outdated staging systems result in patient populations with different underlying risks. This makes direct comparison of outcomes between trials, even for the same drug, an unfair and statistically flawed analysis that ignores the function of a control arm.

Even when testing drugs in heavily pre-treated patients, clinical trials incorporate subtle biological selection criteria. For instance, the COMPASS trial excludes patients with visceral metastases, a tactic to enrich for a population more likely to respond and avoid the most aggressive disease subtypes.

Three 2025 trials (AMPLITUDE, PSMA-addition, CAPItello) introduced personalized therapy for metastatic hormone-sensitive prostate cancer. However, significant benefits were confined to narrow subgroups, like BRCA-mutated patients. This suggests future success depends on even more stringent patient selection, not broader application of targeted agents.

The clinical definition of "high-risk" prostate cancer is evolving due to improved diagnostics. The move from digital rectal exams to more sensitive MRI for T-staging means more patients meet the criteria for being high-risk. This "stage migration" makes it challenging to apply findings from older clinical trials to a contemporary patient population.

The definition of high-volume disease, a key factor in chemotherapy decisions for prostate cancer, has changed across major trials like CHARTERED and STAMPEDE. This evolution, including variations in bone metastases counts and inclusion of Gleason score, complicates cross-trial analysis and highlights its weakness as a surrogate for true disease biology.

The ongoing Alliance ASPIRE trial is one of the first to use tumor biology, specifically alterations in suppressor genes like P10, P53, and RB1, as a primary stratification factor. This marks a significant move away from relying on imaging-based volume criteria (high vs. low) to determine prognosis and predict who may benefit from chemotherapy.